NCT06533761
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06533761
Title Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Stelexis BioSciences
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ESP

Facility Status City State Zip Country Details
City of Hope RECRUITING Duarte California 91010 United States Details
Anshutz Cancer Pavilion RECRUITING Aurora Colorado 80045 United States Details
Moffitt Cancer Center RECRUITING Tampa Florida 33612 United States Details
Dana-Farber Cancer Institute RECRUITING Boston Massachusetts 02215 United States Details
Washington University in St Louis RECRUITING St Louis Missouri 63110 United States Details
Memorial Sloan Kettering Cancer Center NOT_YET_RECRUITING New York New York 10065 United States Details
Memorial Sloan Kettering Cancer Center RECRUITING New York New York 10065 United States Details
Montefiore Medical Center RECRUITING New York New York 10466 United States Details
Cleveland Clinic RECRUITING Cleveland Ohio 44106 United States Details
Ohio State University RECRUITING Columbus Ohio 43210 United States Details
MD Anderson Cancer Center RECRUITING Houston Texas 77054 United States Details
Hospital San Pedro de Alcántara RECRUITING Cáceres 10003 Spain Details
Hospital Universitari i Politècnic La Fe RECRUITING Valencia 46026 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field